A top Bank of England official has urged firms to prioritise AI awareness and cautioned bias will never be fully eliminated.
In patients who had progressed on one prior ARPI, FG3246 plus enzalutamide yielded a median radiographic progression-free survival (rPFS) of 10.1 months and PSA50 response of 40%. Phase I Monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results